There can be no doubt that, for the patient receiving haemodialysis, the importance of how venous access is achieved, managed and maintained is paramount. Despite progress having been made in technique and application, the mainstay of current practice continues to be centred on the formation of arteriovenous fistulae. However, this, and the use of various grafts using synthetic materials, remains beset with problems (Fluck and Kumweda, 2011). These centre on issues to do with infection, clotting (when synthetic substitutes are used) and the inherent challenges in harvesting patient’s own veins, which can be further compromised owing to the patient’s age or other associated pathology, such as diabetes mellitus. On 5 June 2013, surgeons at the Duke University Hospital successfully implanted a bioengineered vein into the arm of a patient suffering from endstage kidney disease, in what is the first stage of a US clinical trial. This may well be seen as one of the most significant steps forward in the ongoing management for this group of patients (Duke Health, 2013). Furthermore, and just as exciting, is the potential for future application in patients with blocked blood vessels (e.g. for use in bypass grafting in cardiac patients) and in the promise it holds out for bioengineering with other organs and tissues. The technology that has enabled this new initiative has been slowly developed over 15 years in collaboration between Laura Niklason and Jeffrey Lawson (Duke Health, 2013). This development can be seen as significant for a number of reasons, as Niklason explained: